Compare NKLR & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKLR | EBS |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.6M | 413.3M |
| IPO Year | 2025 | 2006 |
| Metric | NKLR | EBS |
|---|---|---|
| Price | $5.93 | $5.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $15.00 | $12.00 |
| AVG Volume (30 Days) | 408.9K | ★ 1.4M |
| Earning Date | 04-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.73 | $4.36 |
| 52 Week High | $12.43 | $14.06 |
| Indicator | NKLR | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 51.75 |
| Support Level | $4.01 | $4.36 |
| Resistance Level | $6.47 | $8.59 |
| Average True Range (ATR) | 0.38 | 0.28 |
| MACD | -0.03 | 0.22 |
| Stochastic Oscillator | 46.07 | 98.78 |
Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.